GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
Clinical Trials
768
Active:256
Completed:409
Trial Phases
5 Phases
Phase 1:378
Phase 2:153
Phase 3:67
+2 more phases
Drug Approvals
44
FDA:40
PHILIPPINES:2
SFDA:2
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- Next
Clinical Trials
Distribution across different clinical trial phases (644 trials with phase data)• Click on a phase to view related trials
Phase 1
378 (58.7%)Phase 2
153 (23.8%)Phase 3
67 (10.4%)Phase 4
24 (3.7%)Not Applicable
22 (3.4%)A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
Not Applicable
Not yet recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT07214662
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 312
- Registration Number
- NCT07214766
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib
- First Posted Date
- 2025-08-27
- Last Posted Date
- 2025-10-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT07144111
- Locations
- 🇺🇸
Orange County Research Center, Lake Forest, California, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸The Texas Liver Institute, Inc., San Antonio, Texas, United States
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Not Applicable
Recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-10-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 285
- Registration Number
- NCT07100106
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸City of Hope - Orange County Lennar Foundation Cancer Center, Irvine, California, United States
🇺🇸City of Hope® Cancer Center Chicago, Zion, Illinois, United States
A Study to Evaluate the Relative Bioavailability of Two Tablet Formulations Compared to Capsule Formulation and the Effect of Food and Proton Pump Inhibitor on ZN-A-1041 Tablet(s) in Healthy Participants
- First Posted Date
- 2025-07-04
- Last Posted Date
- 2025-10-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT07051993
- Locations
- 🇬🇧
Fortrea Leeds CRU, Leeds, United Kingdom
- Prev
- 1
- 2
- 3
- 4
- 5
- 101
- Next
News
Tryptase Inhibitor Fails to Meet Primary Endpoint in Asthma Exacerbation Trial
A Phase 2a clinical trial of MTPS9579A, an anti-tryptase antibody, did not significantly reduce the time to first asthma exacerbation event compared to placebo.